On the development of the Medical Research Council trial of alpha-interferon in metastatic renal carcinoma

P M Fayers, P A Cook, D. Machin, N Donaldson, J. Whitehead, A Ritchie, R T Oliver, P. Yuen

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

This paper describes the steps taken by the British Medical Research Council (MRC) in developing the MRC RE01 trial, a randomized clinical trial for patients with metastatic renal cancer; we discuss the reasons for adopting a triangular sequential design and the impact that this has upon the monitoring of the trial. It had been suggested to the MRC that a trial of biological agents for metastatic renal carcinoma should be initiated. The Cancer Therapy Committee (CTC) of the MRC, through its associated site specific working parties, is responsible for designing and co-ordinating randomized trials of alternative treatments in cancer in solid tumours. Since no MRC working party for renal carcinoma existed at that time, development began by the formation of an ad hoc group set up under the auspices of the CTC. They assessed, by means of a postal questionnaire, U.K. interest in the trials of, and modalities utilized for, treatment of renal cancer. The responses focused attention on the important questions to ask and indicated the level of potential collaboration. These responses and related clinical and statistical issues suggested a protocol to compare medroxy-progesterone acetate (MPA) against alpha-interferon (alpha-IFN). In view of the special problems of comparing an expensive and potentially toxic therapy with an inexpensive and non-toxic standard, a sequential design was used rather than a fixed sample size design. Statistical issues raised and solutions provided are described. The method of establishing the trial data monitoring committee and a brief review of mortality from renal carcinoma in England and Wales are also included. The trial opened to patient recruitment on 1 January 1992
Original languageEnglish
Pages (from-to)2249-2260
Number of pages12
JournalStatistics in Medicine
Volume13
Issue number21
DOIs
Publication statusPublished - Nov 1994

Fingerprint

Interferon-alpha
Biomedical Research
Cancer
Carcinoma
Kidney
Kidney Neoplasms
Therapy
Sequential Design
Neoplasms
Clinical Trials Data Monitoring Committees
Therapeutics
Monitoring
Poisons
Wales
Biological Factors
Progesterone
Randomized Clinical Trial
Randomized Trial
England
Sample Size

Cite this

On the development of the Medical Research Council trial of alpha-interferon in metastatic renal carcinoma. / Fayers, P M; Cook, P A; Machin, D.; Donaldson, N; Whitehead, J.; Ritchie, A; Oliver, R T; Yuen, P.

In: Statistics in Medicine, Vol. 13, No. 21, 11.1994, p. 2249-2260.

Research output: Contribution to journalArticle

Fayers, PM, Cook, PA, Machin, D, Donaldson, N, Whitehead, J, Ritchie, A, Oliver, RT & Yuen, P 1994, 'On the development of the Medical Research Council trial of alpha-interferon in metastatic renal carcinoma', Statistics in Medicine, vol. 13, no. 21, pp. 2249-2260. https://doi.org/10.1002/sim.4780132106
Fayers, P M ; Cook, P A ; Machin, D. ; Donaldson, N ; Whitehead, J. ; Ritchie, A ; Oliver, R T ; Yuen, P. / On the development of the Medical Research Council trial of alpha-interferon in metastatic renal carcinoma. In: Statistics in Medicine. 1994 ; Vol. 13, No. 21. pp. 2249-2260.
@article{8944bceebe454835bb9eb4d29f17f371,
title = "On the development of the Medical Research Council trial of alpha-interferon in metastatic renal carcinoma",
abstract = "This paper describes the steps taken by the British Medical Research Council (MRC) in developing the MRC RE01 trial, a randomized clinical trial for patients with metastatic renal cancer; we discuss the reasons for adopting a triangular sequential design and the impact that this has upon the monitoring of the trial. It had been suggested to the MRC that a trial of biological agents for metastatic renal carcinoma should be initiated. The Cancer Therapy Committee (CTC) of the MRC, through its associated site specific working parties, is responsible for designing and co-ordinating randomized trials of alternative treatments in cancer in solid tumours. Since no MRC working party for renal carcinoma existed at that time, development began by the formation of an ad hoc group set up under the auspices of the CTC. They assessed, by means of a postal questionnaire, U.K. interest in the trials of, and modalities utilized for, treatment of renal cancer. The responses focused attention on the important questions to ask and indicated the level of potential collaboration. These responses and related clinical and statistical issues suggested a protocol to compare medroxy-progesterone acetate (MPA) against alpha-interferon (alpha-IFN). In view of the special problems of comparing an expensive and potentially toxic therapy with an inexpensive and non-toxic standard, a sequential design was used rather than a fixed sample size design. Statistical issues raised and solutions provided are described. The method of establishing the trial data monitoring committee and a brief review of mortality from renal carcinoma in England and Wales are also included. The trial opened to patient recruitment on 1 January 1992",
author = "Fayers, {P M} and Cook, {P A} and D. Machin and N Donaldson and J. Whitehead and A Ritchie and Oliver, {R T} and P. Yuen",
year = "1994",
month = "11",
doi = "10.1002/sim.4780132106",
language = "English",
volume = "13",
pages = "2249--2260",
journal = "Statistics in Medicine",
issn = "0277-6715",
publisher = "John Wiley and Sons Ltd",
number = "21",

}

TY - JOUR

T1 - On the development of the Medical Research Council trial of alpha-interferon in metastatic renal carcinoma

AU - Fayers, P M

AU - Cook, P A

AU - Machin, D.

AU - Donaldson, N

AU - Whitehead, J.

AU - Ritchie, A

AU - Oliver, R T

AU - Yuen, P.

PY - 1994/11

Y1 - 1994/11

N2 - This paper describes the steps taken by the British Medical Research Council (MRC) in developing the MRC RE01 trial, a randomized clinical trial for patients with metastatic renal cancer; we discuss the reasons for adopting a triangular sequential design and the impact that this has upon the monitoring of the trial. It had been suggested to the MRC that a trial of biological agents for metastatic renal carcinoma should be initiated. The Cancer Therapy Committee (CTC) of the MRC, through its associated site specific working parties, is responsible for designing and co-ordinating randomized trials of alternative treatments in cancer in solid tumours. Since no MRC working party for renal carcinoma existed at that time, development began by the formation of an ad hoc group set up under the auspices of the CTC. They assessed, by means of a postal questionnaire, U.K. interest in the trials of, and modalities utilized for, treatment of renal cancer. The responses focused attention on the important questions to ask and indicated the level of potential collaboration. These responses and related clinical and statistical issues suggested a protocol to compare medroxy-progesterone acetate (MPA) against alpha-interferon (alpha-IFN). In view of the special problems of comparing an expensive and potentially toxic therapy with an inexpensive and non-toxic standard, a sequential design was used rather than a fixed sample size design. Statistical issues raised and solutions provided are described. The method of establishing the trial data monitoring committee and a brief review of mortality from renal carcinoma in England and Wales are also included. The trial opened to patient recruitment on 1 January 1992

AB - This paper describes the steps taken by the British Medical Research Council (MRC) in developing the MRC RE01 trial, a randomized clinical trial for patients with metastatic renal cancer; we discuss the reasons for adopting a triangular sequential design and the impact that this has upon the monitoring of the trial. It had been suggested to the MRC that a trial of biological agents for metastatic renal carcinoma should be initiated. The Cancer Therapy Committee (CTC) of the MRC, through its associated site specific working parties, is responsible for designing and co-ordinating randomized trials of alternative treatments in cancer in solid tumours. Since no MRC working party for renal carcinoma existed at that time, development began by the formation of an ad hoc group set up under the auspices of the CTC. They assessed, by means of a postal questionnaire, U.K. interest in the trials of, and modalities utilized for, treatment of renal cancer. The responses focused attention on the important questions to ask and indicated the level of potential collaboration. These responses and related clinical and statistical issues suggested a protocol to compare medroxy-progesterone acetate (MPA) against alpha-interferon (alpha-IFN). In view of the special problems of comparing an expensive and potentially toxic therapy with an inexpensive and non-toxic standard, a sequential design was used rather than a fixed sample size design. Statistical issues raised and solutions provided are described. The method of establishing the trial data monitoring committee and a brief review of mortality from renal carcinoma in England and Wales are also included. The trial opened to patient recruitment on 1 January 1992

U2 - 10.1002/sim.4780132106

DO - 10.1002/sim.4780132106

M3 - Article

VL - 13

SP - 2249

EP - 2260

JO - Statistics in Medicine

JF - Statistics in Medicine

SN - 0277-6715

IS - 21

ER -